

LIQUIDIA ACCESS PROGRAMS CAN HELP YOUR PATIENTS START AND STAY ON YUTREPIA

Specialty pharmacy providers can offer information to help patients determine which program might be best for them

The YUTREPIA Voucher Program



The YUTREPIA Voucher Program can provide eligible patients with a one-time, 28-day supply of YUTREPIA to help them determine if it is right for them.*

- Eligible patients will receive support and training from a specialty pharmacy
- For eligible patients wishing to continue therapy, a separate prescription is required†

*Only available for patients who are new to YUTREPIA.

†Continued therapy beyond the Voucher Program is dependent on the patient's insurance coverage.

The YUTREPIA Co-Pay Program



The YUTREPIA Co-Pay Program can provide financial assistance to eligible patients.

- This program is not available to federally insured patients (Medicare, VA TRICARE, and other federal programs)
- For eligible commercially insured patients in need of assistance affording their out-of-pocket cost for YUTREPIA
- Eligible patients may pay as little as \$0 per prescription fill for YUTREPIA, with up to \$8500 in assistance available annually

The YUTREPIA Bridge Program



The YUTREPIA Bridge Program can provide eligible patients who cannot immediately access their prescribed medication with a one-time, 28-day supply of YUTREPIA.

- For eligible patients who have a lapse in insurance coverage or encounter insurance authorization issues that could delay or temporarily prevent them from accessing YUTREPIA

The YUTREPIA Patient Assistance Program



The YUTREPIA Patient Assistance Program can provide medication at no cost to eligible patients in need of assistance affording their out-of-pocket cost for YUTREPIA.

- For eligible patients with a total household adjusted gross income no greater than 500% of the federal poverty level who are unable to afford YUTREPIA due to one of the following:



Not having insurance coverage



Having medical coverage but not having a pharmacy benefit



Having a pharmacy benefit, but YUTREPIA is not covered



Being insured but having exhausted their annual drug cap



Being insured but unable to afford their out-of-pocket expense

- Eligible patients receive their medication for the remainder of the calendar year (subject to annual reapplication/approval)

LIQUIDIA'S PATIENT SUPPORT PROGRAMS ARE PART OF ITS CORPORATE SOCIAL RESPONSIBILITY (CSR) PROGRAM AND ARE NOT COMMERCIAL IN NATURE. PLEASE CONTACT 1-888-393-5732 FOR MORE INFORMATION.

Please see Important Safety Information on reverse and accompanying Full Prescribing Information for YUTREPIA.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

YUTREPIA[™] (treprostinil) is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- Treprostinil may cause symptomatic hypotension.
- Treprostinil inhibits platelet aggregation and increases the risk of bleeding.
- Dosage adjustments may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.
- May cause bronchospasm.
- Patients with a history of hyperreactive airway disease may be more sensitive.

DRUG INTERACTIONS

- Dosage adjustments may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.

USE IN SPECIFIC POPULATIONS

- Safety and effectiveness in pediatric patients have not been established.
- It is unknown if geriatric patients respond differently than younger patients. Caution should be used when selecting a dose for geriatric patients.
- There are no adequate and well-controlled studies with YUTREPIA in pregnant women.
- There are no data on the presence of treprostinil in human milk, the effects on the breastfed infant, or the effects on milk production.
- Treprostinil has not been studied in patients with severe hepatic insufficiency.

ADVERSE REACTIONS

- Most common adverse reactions with YUTREPIA (≥10%) are cough, headache, throat irritation, and dizziness.

Please see accompanying Full Prescribing Information for YUTREPIA.

**LEARN HOW
TO GET YOUR
PATIENTS WITH
PAH AND PH-ILD
STARTED ON
YUTREPIA**



**Scan code
to download
enrollment form**

WHO = World Health Organization.